ABVC BioPharma to Distribute 4.5M BioKey Shares as 15% Spin-Off Dividend
ABVC•ABVC BioPharma will spin off its BioKey subsidiary by distributing approximately 4,500,000 new BioKey shares, representing about 15% of outstanding shares, as a pro rata dividend to shareholders of record on July 24, 2026. The distribution in book-entry form via VStock Transfer is expected effective August 3, 2026, with BioKey seeking OTC Market quotation post-distribution.
1. Planned Spin-Off and Distribution Details
ABVC intends to distribute approximately 4,500,000 Ordinary Shares of BioKey, representing about 15% of BioKey's outstanding shares, as a pro rata dividend to shareholders of record as of July 24, 2026. The distribution will be effected in book-entry form through VStock Transfer with no shareholder action or consideration required and is expected to be effective at 11:59 p.m. ET on August 3, 2026.
2. BioKey's Business Operations and OTC Listing Plan
BioKey (Cayman), through its subsidiary BioKey, Inc., operates as a fully integrated CRO/CDMO platform offering nutraceutical and functional-supplement research, formulation development, cGMP manufacturing, and regulatory support across Asia and North America. Post-distribution, BioKey plans to apply for quotation of its Ordinary Shares on the OTC Markets, though timing and market liquidity remain uncertain until a trading market develops.
3. Strategic Rationale and Value Creation
The spin-off aligns with ABVC’s strategy to highlight subsidiary value and deliver direct participation in BioKey’s growth to shareholders. Management views the transaction as a milestone in unlocking value, enhancing visibility, and providing strategic flexibility for both ABVC and BioKey while exploring additional value-enhancing opportunities in biotechnology and AI platforms.
